GILD Gilead Sciences

Q3 2025 10-Q

Filed: Nov 7, 2025Period ending Sep 30, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Gilead Sciences (GILD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• No specific quarterly revenue or YoY change data provided in the section
• No profitability or margin figures disclosed for the quarter

+3 more insights

Risk Factors

• New regulatory risk: FDA boxed warning (Jan 2024) on CAR T-cell therapies for secondary T-cell malignancies; impacts Yescarta, Tecartus acceptance
• Updated pricing risk: Inflation Reduction Act effects uncertain; increased Medicare Part D discounts (10%-20%) and rebate obligations starting 2023-2025

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$7.8B

▲ +3.0% YoY▲ +9.7% QoQ

Net Income

$3.1B

▲ +143.6% YoY▲ +55.7% QoQ

Operating Margin

42.8%

▲ +3105bp YoY▲ +789bp QoQ

Net Margin

39.3%

▲ +2268bp YoY▲ +1161bp QoQ

ROE

14.2%

Total Assets

$58.5B

EPS (Diluted)

$2.43

▲ +140.6% YoY▲ +54.8% QoQ

Operating Cash Flow

$4.1B

▼ -4.7% YoY▲ +396.7% QoQ

Source: XBRL data from Gilead Sciences Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Gilead Sciences Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Gilead Sciences

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.